Current prospective of anti-il-4, -il-9, and -il-13 therapies in allergic disease

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 3, 2010, Pages 222-230

  Steinke, John W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antibody; Asthma; Atopy; Immunomodulation; Interleukin 13; Interleukin 4; Interleukin 9; Lymphocytes

Indexed keywords

AIR 645; AMG 317; COMPLEMENTARY RNA; FAS ANTIGEN; IMA 638; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 9; INTERLEUKIN 9 RECEPTOR; MEDI 528; MONOCLONAL ANTIBODY; MUCIN; MUCIN 2; MUCIN 5AC; NEW DRUG; PITRAKINRA; PLACEBO; QAX 576; RECOMBINANT INTERLEUKIN 4; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AIRWAY; AIRWAY HYPERRESPOSIVENESS; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIGEN EXPRESSION; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; B LYMPHOCYTE; BASOPHIL; BIOLOGICAL THERAPY; BRONCHUS MUCOSA; CD4+ T LYMPHOCYTE; CELL HYPERPLASIA; CELL INFILTRATION; CHEST INFECTION; CLINICAL OBSERVATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; EOSINOPHIL; EOSINOPHILIC ESOPHAGITIS; FIBROSING ALVEOLITIS; GOBLET CELL; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; LUNG FIBROBLAST; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTE DIFFERENTIATION; MAST CELL; MONOCYTE; MUCUS SECRETION; NEBULIZATION; NEUTROPHIL; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RESPIRATORY EPITHELIUM; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 78649376934     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310793564281     Document Type: Article

References (82)

1. Ginde AA, Espinola JA, Camargo CAJ. Improved overall trends but persistent racial disparities in emergency department visits for acute asthma, 1993-2005. J Allergy Clin Immunol 2008; 122: 313-8.
2. Crystal-Peters J, Neslusan CA, Smith MW, Togias A. Health care costs of allergic rhinitis-associated conditions vary with allergy season. Ann Allergy Asthma Immunol 2002; 89: 457-62.
3. Connolly CK, Alcock SM, Prescott RJ. Mortality in asthmatics over 15 yrs: A dynamic cohort study from 1983-1998. Eur Respir J 2002; 19: 593-8.
4. Steinke JW, Rich SS, Borish L. Genetics of allergic disease. J Allergy Clin Immunol 2008; 121: S384-7.
5. Steinke JW. The relationship between rhinosinusitis and asthma sinusitis. Curr Allergy Asthma Rep 2006; 6: 495-501.
6. Krouse JH, Brown RW, Fineman SM, Han JK, Heller AJ, Joe S, et al. Asthma and the unified airway. Otolaryngol Head Neck Surg 2007; 136: S75-S106.
7. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065-9.
8. Seder RA, Paul WE, Davis MM, Fazekas de St. Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-8.
9. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-8.
10. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 1987; 5: 429-59.
11. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopoly- saccharide-activated B cells. J Immunol 1986; 136: 4538-41.
12. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997; 99: 1492-9.
13. Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, et al. Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 2006; 61: 1047-53.
14. Zaitsu M, Hamasaki Y, Matsuo M, Kukita A, Tsuji K, Miyazaki M, et al. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. Blood 2000; 96: 601-9.
15. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate immunoglobulin E- dependent cysteinyl leukotriene production by human cord blood- derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J Exp Med 2001; 193: 123-33.
16. Early SB, Barekzi E, Negri J, Hise K, Borish L, Steinke JW. Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-g on peripheral immune cells. Am J Respir Cell Mol Biol 2007; 36: 715-20.
17. Moser R, Fehr J, Bruijnzeel PL. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992; 149: 1432-8.
18. Hoontrakoon R, Kailey J, Bratton D. IL-4 and TNF-alpha synergize to enhance eosinophil survival. J Allergy Clin Immunol 1999; 103: A239.
19. Luttmann W, Matthiesen T, Matthys H, Virchow JCJ. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor- alpha on eosinophil activation in vitro. Am J Respir Cell Mol Biol 1999; 20: 474-80.
20. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med 1997; 36: 179-85.
21. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4 (IL-4) or IL-7 prevents death of resting T cells: Stat-6 is probably not required for the effect of IL-4. J Exp Med 1997; 186: 325-30.
22. Izuhara K, Shirakawa T. Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 1999; 3: 3-10.
23. Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GKK, Kolls JK, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol 2009; 182: 5317-21.
24. Newcomb DC, Zhou W, Goleniewska K, Peebles Jr RS. Human CD4+ Th17 cells express a functional IL-13 receptor and IL-13 signaling negatively regulates IL-17A production. J Allergy Clin Immunol 2010; 125: AB117.
25. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, et al. The murine IL-13 receptor alpha 2: Molecular cloning, characterzation, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998; 161: 2317-24.
26. Chen W, Sivaprasad U, Tabata Y, Gibson AM, Stier MT, Finkelman FD, et al. IL-13R 2 membrane and soluble isoforms differ in humans and mice. J Immunol 2009; 183: 7870-6.
27. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL- 13 signaling through the IL13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
28. Shi HZ, Deng JM, Xu H, Nong ZX, Xiao CQ, Liu ZM, et al. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. Am J Respir Crit Care Med 1998; 157: 1818-21.
29. Daher S, Santos LM, Sole D, De Lima MG, Naspitz CK, Musatti CC. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J Invest Allergol Clin Immunol 1995; 5: 251-4.
30. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T- lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
31. Parronchi P, De Carli M, Manetti R, Simonelli C, Piccinni MP, Macchia D, et al. Aberrant interleukin (IL)-4 and IL-5 production in vitro by CD4+ helper T cells from atopic subjects. Eur J Immunol 1992; 22: 1615-20.
32. Chan SC, Brown MA, Willcox TM, Li SH, Stevens SR, Tara D, et al. Abnormal IL-4 gene expression by atopic dermatitis T lymphocytes is reflected in altered nuclear protein interactions with IL-4 transcriptional regulatory element. J Invest Dermatol 1996; 106: 1131-6.
33. Leonard C, Tormey V, Burke C, Poulter LW. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am J Respir Crit Care Med 1997; 17: 368-75.
34. Piccinni MP, Beloni L, Giannarini L, livi C, Scarselli G, Romagnani S, et al. Abnormal production of T helper 2 cytokines interleukin-4 and interleukin-5 by T cells from newborns with atopic parents. Eur J Immunol 1996; 26: 2293-8.
35. Izuhara K, Arima K, Kanaji S, Ohta S, Kanaji T. IL-13: A pro- mising therapeutic target for bronchial asthma. Curr Med Chem 2006; 13: 2291-8.
36. Siddiqui S, Cruse G, McKenna S, Monteiro W, Mistry V, Wardlaw A, et al. IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis. BMC Pulm Med 2009; 9: 34.
37. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major sub- phenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-95.
38. Yasuo M, Fujimoto K, Tanabe T, Yaegashi H, Tsushima K, Takasuna K, et al. Relationship between calcium-activated chloride channel 1 and MUC5AC in goblet cell hyperplasia induced by interleukin-13 in human bronchial epithelial cells. Respir Med 2003; 100: 1360-7.
39. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Lung Cell Mol Physiol 2003; 285: 730-9.
40. Kettle R, Simmons J, Schindler F, Jones P, Dicker T, Dubois G, et al. Regulation of neuregulin 1ss1-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol 2010: 42(4): 472-81.
41. Malavia NK, Mih JD, Raub CB, Dinh BT, George SC. IL-13 induces a bronchial epithelial phenotype that is profibrotic. Respir Res 2008; 9: 27.
42. Vedhoen M, Uyttenhove C, Van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9- producing subset. Nat Immunol 2008; 9: 1341-6.
43. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Fox3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008; 9: 1347-55.
44. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20: 1413-6.
45. Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, et al. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol 1999; 29: 2130-9.
46. Fawaz LM, Sharif-Askari E, Hajoui O, Soussi-Gounni A, Hamid Q, Mazer BD. Expression of IL-9 receptor a chain on human germinal center B cell modulates IgE secretion. J Allergy Clin Immunol 2007; 120: 1208-15.
47. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, et al. IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 1999; 103: 485-91.
48. Gounni AS, Hamid Q, Rahman SM, Hoeck J, Yang J, Shan L. IL- 9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol 2004; 173: 2771-9.
49. Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin HE, McKenzie ANJ. IL-9-deficient mice establish fundemental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13: 573-83.
50. Louahed J, Toda M, Jen J, Hamid Q, Renauld J-C, Levitt RC, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000; 22: 649-56.
51. Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, McKenzie A, et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178: 3244-51.
52. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic disease: Increased expression in asthma. J Allergy Clin Immunol 1999; 104: 108-15.
53. Ying S, Meng Q, Kay AB, Robinson D. Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: Relationships to eosinophils, mast cells and T lymphocytes. Clin Exp Allergy 2002; 32: 866-71.
54. Jenmalm MC, Van Snick J, Cormont F, Salman B. Allergeninduced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin Exp Allergy 2001; 31: 1528-35.
55. Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol 2003; 111: 1319-27.
56. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: Multi-component, highaffinity blockers of cytokine action. Nat Med 2003; 9: 47-52.
57. Losman JA, Chen XP, Hilton D, Rothman P. SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 1999; 162: 3770-4.
58. McCusker CT, WAng Y, Shan J, Kinyanjui MW, Villeneuve A, Michael H, et al. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J Immunol 2007; 179: 2556-64.
59. Tepper, J., Tomkinson, A. Methods and composition for treating asthma in human and non human primates. US20070212308 (2007).
60. Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, et al. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 2010; 65(1): 69-77.
61. Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/ pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009; 49: 1025-36.
62. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2A studies. Lancet 2007; 370: 1422-31.
63. Tocker J, Raminfar L, Barone C. Effects of an antibody to IL-4R in a mouse asthma model. Am J Respir Crit Care Med 2001; 163: A523.
64. Pluenneke, J.D. Use of interleukin-4 antagonists and compositions thereof. US20090104662 (2009).
65. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, and IL-4R antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181(8): 788-96.
66. Karras, J.G., Gregory, S., Freier, S.M., Dobie, K.W. Compositions and their uses directed to IL-4R alpha. US20090281169 (2009).
67. Karras, J.G., Gregory, S.,Crosby, J. R., Guha, M., Tung, D., Freier, S. M. Compositions and their uses directed to IL-4R alpha US20090312398 (2009).
68. Campbell, E., Parveen, S., Buechler, J., Valkirs, G. Anti-IL13 human antibodies. US20080267959 (2008).
69. Fung, S. C., Moyle, M., Lu, M., Yan, C., Singh, S., Huang, D. Novel anti-IL13 antibodies and uses thereof. US20090214523 (2009).
70. Fish, B.C., Langstone, J.E., Bannister, K., Hope, C.L. Interleukin- 13 antibody composition. US20080248048 (2008).
71. Kasaian, M. T., Tchistiakova, L.G., Veldman, G. M., Marquette, K. A., Tan, X.-Y., Donaldson, D. D., Lin, L. L., Shane, T., Tam, A. S. P., Feyfant, E., Wood, N. L., Fitz, L. J., Widom, A. M., Parris, K. D., Goldman, S. J., Saldanha, J. W. Antibodies against human interleukin-13 and uses there for. US20100129360 (2010).
72. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerabilty of repeat dosing with a human IL-13 antibody (CAT- 354) in subjects with asthma. BMC Pulm Med 2010; 10: 3.
73. Barry, A.B., Crowley, T.J., Dixon, D. A., Soley, E.C. Anti-IL-13 antibody formulations and uses thereof. US20090060906 (2008).
74. Swanson, R.V., Chi, E., Raghunathan, G., Zhao, S., Fransson, J., Cordier, W., Zhou, H. M., Almagro, J. C., Hyun, L., Giles-Komar, J., O'Neil, K.T., Carton, J.M., Teplyakov, A. V. Engineered anti- IL-13 antibodies, compositions, methods and uses. US20100111959 (2010).
75. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, Ahmed A, et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007; 36: 368-76.
76. Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan XY, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007; 119: 1251-7.
77. Reed, J.L., Wu, H., Tang, Y., Davies, J., Walkins, J.D. Recombinant IL-9 antibodies. US7354584 (2008).
78. Reed, J. L., Wu, H.,Tang, Y., Davies, J., Watkins, J. D. Recombinant IL-9 antibodies and uses thereof. US20090047277 (2009).
79. White B, Leon F, White W, Robbie G. Two first-in-human, openlabel, phase I dose escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther 2009; 31: 728-40.
80. LaForce C, Boulet L-P, Pearlman D, Fogarty C, Miller SD, Gauvreau G, et al. Multiple subcutaneous doses of MDEI-528, a monoclonal antibody against interleukin-9 in mild and moderate asthmatics. Chest Meet Abstracts 2008; 134: s43002.
81. D'Souza B, Mlyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene 2008; 27: 5148-67.
82. Amsen D, Antov A, Flavell RA. The different faces of Notch in Thelper- cell differentiation. Nat Rev Immunol 2009; 9: 116-24.